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To the Editor — In the Second Regulatory 
Review on Nanomaterials1, the European 
Commission acknowledges that 
nanomaterials are revolutionary materials 
and that important challenges exist in regard 
to hazard and exposure assessments. Yet, 
they conclude that current risk-assessment 
methods are applicable to nanomaterials, 
and that the European chemical legislative 
(known as REACH: Registration, Evaluation, 
Authorisation and Restriction of Chemicals) 
“…sets the best possible framework for 
the risk management of nanomaterials”1. 
Here, I argue that significant changes to 
REACH and the accompanying annexes 
are required to answer the call made 
by the public, downstream users and 
progressive businesses for clearer and 
more definite regulatory rules specific to 
nanomaterials2.
Under REACH, unambiguous substance 
identification is essential3. Briefly, a chemical 
substance is defined by its chemical 
composition including any additive used to 
preserve stability and any impurity derived 
from the processes used for its manufacture4. 
Substance identity is therefore independent 
of, for instance, primary particle size 
distribution and various surface treatments, 
which are necessary to stabilize the substance. 
This means nanomaterials with markedly 
different properties — for example, the bulk 
and nanoform of a material, or various forms 
of surface-treated nanomaterials5,6 — are 
considered to be the same under REACH. 
In the European Commission’s Staff Working 
Paper7, which accompanies the Second 
Regulatory Review on Nanomaterials1, over 60 
nanomaterials are cited to be on the market. 
Yet, a survey by the European Commission 
and the European Chemicals Agency 
(ECHA) found only seven nanomaterials 
were registered under REACH in the first 
round of registrations in 2010 as — among 
others — substances that were produced and 
imported at >1,000 tons per year7,8.
For correct and unambiguous substance 
identification, a distinction between the bulk 
and the nanoforms of a given material needs 
to be specified in the legal text of REACH9. 
Furthermore, the European Commission 
should acknowledge that nanomaterials 
cannot be identified solely by chemical 
composition, and that additional main 
identifiers (such as primary particle size 
distribution, shape (including aspect ratio), 
specific surface area and surface treatment) 
should be included in the Technical Guidance 
for Identification and Naming of  Substances 
provided by ECHA3. Only this will make 
clear that the properties and behaviour of 
nanomaterials differ fundamentally from 
each other and from the bulk5.
Specific substance identification of 
nanomaterials could mean that some would 
not meet REACH’s tonnage bands, which 
lay down the environmental, health and 
safety information requirements that need 
to be met by industry. Although lowering 
the tonnage band to, for example, 1 kg 
(ref. 10) has been suggested, I contend 
that if nanomaterials are commercialized 
in Europe, their registration should be 
independent of production volumes, and 
submission of (eco)toxicological data to 
regulators should be mandatory. Moreover, 
given the urgency of generating data on 
nanomaterials, registration fees must be 
reduced to encourage registration. As 
recommended by the consortium contracted 
by the European Commission to advise 
on fulfilling information requirements for 
nanomaterials under REACH, manufacturers 
should be required to perform accurate 
physicochemical characterization using 
multiple techniques because this is essential 
for assessing the potential (eco)toxicity of 
nanomaterials11. Furthermore, ECHA should 
offer confidential technical assistance to 
small- and medium-sized enterprises to 
meet these requirements and to ensure the 
innovation of safe nanomaterials12.
In contrast to the Second Regulatory 
Review on Nanomaterials1, the Staff Working 
Paper7 highlights many of the challenges 
mentioned here and acknowledges that much 
more research and legislative grinding-out 
is needed. For instance, it recognizes that 
the information in REACH registrations 
pertaining to nanoform(s) is ambiguous, 
further underlining the importance of having 
REACH and the Guidance for Identification 
and Naming of Substances consider 
nanospecific properties and implement 
specific requirements for (eco)toxicological 
information. Furthermore, the Staff Working 
Paper acknowledges that nanomaterials 
may have a wide range of potential toxic 
effects, that there are few measured exposure 
data and that few environmental fate and 
behaviour studies are available. It concludes 
that “…risk characterisation and combining 
hazard and exposure data necessarily remains 
at a very preliminary and qualitative level”7. 
Unfortunately, the limitations of current 
regulation and risk-assessment approaches 
outlined in it were not transferred to the 
Second Regulatory Review on Nanomaterials1.
Referring to the 2009 report13 of the 
Scientific Committee on Emerging and 
Newly Identified Health Risks (SCENIHR), 
the European Commission repeatedly 
calls for a case-by-case risk assessment of 
nanomaterials. However, the issues crippling 
hazard identification are not easily overcome 
and merit more than a few caveats as 
stated by the European Commission1. For 
instance, hazard-relevant physicochemical 
properties still need to be identified for 
nanomaterials. Furthermore, there are 
currently no standardized (eco)toxicity test 
guidelines in use11. Moreover, monitoring 
and detection equipment for exposure 
assessment need to be developed and 
there are no standards on how to measure 
nanoparticle dose in humans, the workplace 
and the environment14. Even if required only 
for commercialized nanomaterials, case-
by-case risk assessment of nanomaterials is 
time- and resource-intensive15 as outlined in 
the 2012 report by SCENIHR and two other 
scientific committees16. Under the heading 
‘5.2.Towards a new conceptual framework 
in risk assessment’, the report states “It 
is also evident that the risks posed by a 
number of products from new technologies 
(for example, biological products, 
manufactured nanomaterials) are unlikely 
to be adequately assessed using current 
methodologies alone”16.
Another disturbing aspect of the Second 
Regulatory Review on Nanomaterials1 is 
that it focuses only on first-generation 
nanomaterials (that is, passive nanostructures 
such as nanoparticles). The Staff Working 
Paper7 acknowledges that second- and 
third-generation nanomaterials (for 
example, targeted drug-delivery systems 
and novel robotic devices) are entering 
early stages of market development, yet 
they offer no vision or strategic planning in 
ensuring the generation and development of 
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environmental, health and safety information, 
and regulations in a timely manner.
Finally, the European Commission 
repeatedly downplay the concerns by stating 
that1 “…nanomaterials are similar to normal 
chemicals/substances in that some may 
be toxic and some may not.” The analogy 
highlights that manufacturers, scientists and 
the European Commission are not aware of 
which nanomaterials are toxic just as we did 
not know about industrial chemicals before 
they came into widespread use during the 
twentieth century, resulting in significant 
human health and environmental damage as 
documented by the European Environmental 
Agency17,18. One fears that the European 
Commission either does not understand 
the challenges and problems before them 
when it comes to regulation and risk 
assessment of nanomaterials, or they grossly 
underestimate them. ❐
References
1. European Commission. Second Regulatory Review on 
Nanomaterials (2012); available via http://go.nature.com/2bPFN7
2. Engeman, C. D. et al. J. Nanopart. Res. 14, 749 (2012). 
3. European Chemicals Agency (ECHA). Guidance for Identification 
and Naming of Substances under REACH and CLP (2012); 
available via http://go.nature.com/vL4KzJ
4. European Parliament and Council of European Union; available 
via http://go.nature.com/dIpYxp 
5. Joint Research Centre. REACH Implementation Project Substance 
Identification of Nanomaterials (RIP-oN 1) (2011); available via 
http://go.nature.com/ENYrM8. 
6. Department for Environment, Food and Rural Affairs (DEFRA); 
available via http://go.nature.com/gkTicd 
7. European Commission. Commission Staff Working Paper (2012); 
available via http://go.nature.com/Hebkwm
8. Joint Research Centre. Scientific Technical Support on Assessment 
of Nanomaterials in REACH Registration Dossiers and Adequacy of 
Available Information (2012); available via http://go.nature.com/
BXyWYh
9. Franco, A. et al. Regul. Toxicol. Pharmacol. 48, 171–183 (2007).
10. ClientEarth; http://www.clientearth.org/reports/high-time-to-act-
 on-nanomaterials.pdf
11. European Commission. Specific Advice on Fulfilling Information
 Requirements for Nanomaterials under REACH (RIP-oN 2) (2011); 
available via http://go.nature.com/UCXbYh
12. Hansen, S. F. & Tickner, J. Nanotechnol. Law Business
 4, 341–359 (2007).
13. Scientific Committee on Emerging and Newly Identified Health
 Risks (SCENIHR). Risk Assessment of Products of Nanotechnologies 
(2009); available via http://go.nature.com/Lcz5mn
14. European Commission. Specific Advice on Exposure Assessment 
and Hazard/Risk Characterisation for Nanomaterials under REACH 
(RIP-oN 3) (2011); available via http://go.nature.com/kSinBH 
15. Commission of the European Communities. Strategy for a Future 
Chemicals Policy (2001); available via http://go.nature.com/
M9NcgV
16. Scientific Committee on Emerging and Newly Identified Health 
Risks (SCENIHR). Addressing the New Challenges for Risk 
Assessment (2012); available via http://go.nature.com/8Pd3ws
17. European Environment Agency. Late Lessons from Early 
Warnings: the Precautionary Principle 1896–2000 (2002); available 
via http://go.nature.com/F8kLAL 
18. European Environment Agency. Late Lessons from Early 
Warnings: Science, Precaution, Innovation (2013); available via 
http://go.nature.com/aJXkKt
Steffen Foss Hansen 
Department of Environmental Engineering, 
Technical University of Denmark, 2800 Kgs. 
Lyngby, Denmark.  
e-mail: sfha@env.dtu.dk
To the Editor — In the preceeding 
Correspondence piece ‘The European 
Union’s chemical legislation needs revision’ 
(Nature Nanotech. 8, 305–306; 2013) 
Hansen focuses on substance identification 
as being a key issue in bringing clarity on 
the different properties of the bulk- and 
nanoforms of the same substance; in the 
extreme interpretation, all nanoforms 
would be considered as different substances. 
It argues that nanomaterials should be 
registered independently of their tonnage.
In particular, it claims that “the European 
Commission should acknowledge that 
nanomaterials cannot be identified solely by 
chemical composition, and that additional 
main identifiers (such as primary particle size 
distribution, shape (including aspect ratio), 
specific surface area and surface treatment) 
should be included in the Technical Guidance 
for Identification and Naming of Substances 
provided by ECHA”, and, that “Only this will 
make clear that the properties and behaviour 
of nanomaterials differ fundamentally from 
each other and from the bulk.” This suggests 
that those additional main identifiers are 
the main solution to clearly identifying 
differences between the properties and 
behaviour of nanomaterials from their 
corresponding bulk forms and among each 
other (for example, the same nanopowder 
of different diameters, or with different 
surface coatings).
The European Commission has 
committed to further work on substance 
identification. However, this is only 
one element to getting clarity on the 
differences between the properties and 
behaviour of nanomaterials. Trying to 
identify unambiguous rules for substance 
identification for all cases is probably elusive 
and might result in ever more complex 
rules on what is considered as the same 
substance as opposed to different substances, 
without necessarily resulting in more safety 
of nanomaterials. Rather, we consider 
that focusing on clarifying what is needed 
to demonstrate the safe use — whether 
that is done in one or several dossiers 
— is more promising to make progress 
on nanomaterial safety. (See the Second 
Regulatory Review on Nanomaterials, section 
5.2; http://go.nature.com/2bPFN7) 
Clarifying the rules on how to 
demonstrate the safe use of nanomaterials is 
the purpose of the envisaged amendment to 
the annexes of the Registration, Evaluation, 
Authorisation and Restriction of Chemicals 
(REACH) regulation, as outlined in section 
5.1 of the Second Regulatory Review on 
Nanomaterials. Because co-decision 
regulation requires several years of 
legislative work, changes to the annexes 
(which can be done in a time frame of one 
to two years) are the most promising route 
to rapidly getting more clarity on which 
nanomaterials are covered in the REACH 
registration dossiers, to address specificities 
on the risk assessment of nanomaterials and 
to generate more information on their 
hazards and risks. Clearly, this should be 
supported by efforts from Member States 
to engage in substance evaluation, and to 
launch a dialogue between authorities and 
registrants to identify unclear information 
and remaining information gaps, as well as 
ways to fill in those gaps.
Furthermore, Hansen claims that 
registration of nanomaterials “should be 
independent of production volumes, and 
submission of (eco)toxicological data to 
regulators should be mandatory”. However, 
it fails to argue why nanomaterials should 
be treated differently from other chemicals 
in this respect. In particular, it does not give 
evidence that nanomaterials as a category 
of substances are more hazardous than 
other chemical substances, nor that the 
risks of hazardous nanomaterials are more 
severe than those of conventional hazardous 
chemicals. Therefore, it is unclear why 
lower or no tonnage thresholds for REACH 
registration should apply to nanomaterials 
compared with other chemical substances.
The one-tonne-registration threshold 
for chemicals has been agreed between the 
co-legislators of the European Parliament 
and Council as an appropriate balance 
between ensuring that a maximum of 
Substance identification of nanomaterials 
not key to ensuring their safe use
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